From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. Cardiology>
  4. Summary and Comment

What’s the Utility of the Apo B:Apo A-1 Ratio?

In a large, prospective study, apolipoproteins had no advantage over other lipid measures in assessing risk for CHD.

Multiple tests have been touted to improve the prediction of coronary heart disease. Several published clinical guidelines have recommended the use of apolipoprotein B (apo B) for this purpose; however, this approach has not been validated. Therefore, investigators used a variety of techniques to evaluate the relative utility of apo B, apolipoprotein A-1 (apo A-1), serum total cholesterol, HDL cholesterol, LDL cholesterol, non-HDL cholesterol, and three lipid ratios in determining risk for CHD, as well as the relative ability of these measures to reclassify CHD risk. More than 3300 middle-aged, white participants in the Framingham Offspring Study without cardiovascular disease were followed for a median of 15 years.

A total of 291 first CHD events occurred, 198 of them in men. In men, elevations in non-HDL cholesterol, apo B, total cholesterol:HDL ratio, LDL:HDL ratio, and apo B:apo A-1 ratio were all significantly associated with increased CHD risk to a similar degree. Elevated apo A-1 and HDL were likewise associated with reduced CHD risk. Women had results similar to those in men except that decreased apo A-1 was not significantly associated with incident CHD. In sex-specific analyses, elevated LDL and total cholesterol were not significantly associated with increased CHD risk in either men or women, perhaps owing to the lack of statistical power of these substudies. In men, total cholesterol:HDL and apo B:apo A-1 ratios both improved reclassification of 10-year risk for CHD; however, the difference between the two was not significant. In women, neither lipid ratio improved CHD risk reclassification.

Comment: This large, population-based, cohort study suggests that measuring total cholesterol and HDL appears to suffice to determine heart disease risk. The apo B:apo A-1 ratio has little clinical utility in predicting incident CHD.

JoAnne M. Foody, MD

Published in Journal Watch Cardiology August 22, 2007

Citation(s):

Ingelsson E et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007 Aug 15; 298:776-85.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2007. Massachusetts Medical Society. All rights reserved.